EGFR and neoplasm: In view of the above evidence, the American Society of Clinical Oncology (ASCO) put forth guidelines in 2009 stating that all mCRC patients must undergo tests for KRAS mutations in their tumor tissue prior to initiating treatment with anti-EGFR antibodies.